Oramed Pharmaceuticals Inc (ORMP):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Oramed Pharmaceuticals Inc (ORMP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10061
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イスラエル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oramed Pharmaceuticals Inc (Oramed) engages in the research and development of novel pharmaceutical solutions, comprising an oral insulin capsule for the treatment of individuals with diabetes, and orally ingestible capsules or pills for delivery of other polypeptides. It developed a unique proprietary platform technology, Protein Oral Delivery (POD) to transform injectable treatments into oral therapies. The technology allows for the oral delivery of drugs currently administered only by injection. The company tested its technology through various animal and human studies on its two flagship products, ORMD-0801, an orally ingestible insulin capsule; and ORMD-0901, an oral GLP-1 analog (exenatide) capsule. Oramed is headquartered in Jerusalem, Israel.

Oramed Pharmaceuticals Inc (ORMP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Hefei Tianhui Incubator of Technologies Amends Its Licensing Agreement with Oramed Pharma 11
Oramed to Enter into Licensing Agreement with Sinopharm and Hefei Life Science 12
Guangxi Wuzhou Pharma Enters into Licensing Agreement with Oramed Pharma 13
Equity Offering 14
Oramed Pharma Raises USD18.1 Million in Private Placement of Shares 14
Oramed Pharma to Raise up to USD25 Million in Public Offering of Shares 16
Oramed Pharma Raises USD12 Million in Private Placement of Shares 17
Oramed Pharma Raises USD5.4 Million in Private Placement of Shares 18
Oramed Pharma to Raise USD5.4 Million in Private Placement of Shares 20
Oramed Pharma Completes Private Placement Of Shares For US$15.8 Million 21
Oramed Pharma Completes Private Placement Of Shares For US$4.6 Million 23
Oramed Pharma Withdraws Public Offering Of Common Stock For US$13 Million 24
Oramed Pharma Completes Private Placement Of Units US$5 Million 25
Oramed Pharma Completes Private Placement Of Units For US$3.6 Million 26
Acquisition 27
Sinopharm and Hefei Life Science to Acquire 10% Stake In Oramed Pharma 27
Guangxi Wuzhou Pharma Acquires Stake in Oramed Pharma for USD5 Million 28
Oramed Pharmaceuticals Inc – Key Competitors 29
Oramed Pharmaceuticals Inc – Key Employees 30
Oramed Pharmaceuticals Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Joint Venture 31
Recent Developments 32
Corporate Communications 32
Feb 28, 2018: Oramed Appoints Robert Henry and Jane Reusch to its Scientific Advisory Board 32
Mar 21, 2017: Oramed Appoints Dr. Ronald Law as Chief Strategy Officer 33
Product News 34
05/02/2017: Oramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oramed Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Hefei Tianhui Incubator of Technologies Amends Its Licensing Agreement with Oramed Pharma 11
Oramed to Enter into Licensing Agreement with Sinopharm and Hefei Life Science 12
Guangxi Wuzhou Pharma Enters into Licensing Agreement with Oramed Pharma 13
Oramed Pharma Raises USD18.1 Million in Private Placement of Shares 14
Oramed Pharma to Raise up to USD25 Million in Public Offering of Shares 16
Oramed Pharma Raises USD12 Million in Private Placement of Shares 17
Oramed Pharma Raises USD5.4 Million in Private Placement of Shares 18
Oramed Pharma to Raise USD5.4 Million in Private Placement of Shares 20
Oramed Pharma Completes Private Placement Of Shares For US$15.8 Million 21
Oramed Pharma Completes Private Placement Of Shares For US$4.6 Million 23
Oramed Pharma Withdraws Public Offering Of Common Stock For US$13 Million 24
Oramed Pharma Completes Private Placement Of Units US$5 Million 25
Oramed Pharma Completes Private Placement Of Units For US$3.6 Million 26
Sinopharm and Hefei Life Science to Acquire 10% Stake In Oramed Pharma 27
Guangxi Wuzhou Pharma Acquires Stake in Oramed Pharma for USD5 Million 28
Oramed Pharmaceuticals Inc, Key Competitors 29
Oramed Pharmaceuticals Inc, Key Employees 30
Oramed Pharmaceuticals Inc, Subsidiaries 31
Oramed Pharmaceuticals Inc, Joint Venture 31

List of Figures
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Oramed Pharmaceuticals Inc (ORMP):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Latam Airlines Group S.A.:企業の戦略・SWOT・財務分析
    Latam Airlines Group S.A. - Strategy, SWOT and Corporate Finance Report Summary Latam Airlines Group S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • LivaNova PLC (LIVN):医療機器:M&Aディール及び事業提携情報
    Summary LivaNova PLC (LivaNova) is a medical technology company that offers medical devices for cardiac surgery and neuromodulation. The company’s neuromodulation provides vagus nerve stimulation therapy system, an implantable device for the people affected by treatment-resistant epilepsy, depressio …
  • Nishat Mills Ltd:企業の戦略・SWOT・財務情報
    Nishat Mills Ltd - Strategy, SWOT and Corporate Finance Report Summary Nishat Mills Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Sientra Inc (SIEN):企業の財務・戦略的SWOT分析
    Summary Sientra Inc (Sientra) is a medical device company that manufactures and markets plastic surgery implantable devices. The company’s products comprise breast implants, breast tissue expanders, silicone scar treatment and additional tissue expanders. It offers reconstructive surgery devices suc …
  • Calamos Asset Management, Inc.
    Calamos Asset Management, Inc. - Strategy, SWOT and Corporate Finance Report Summary Calamos Asset Management, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Ipsen S.A.:企業の戦略・SWOT・財務情報
    Ipsen S.A. - Strategy, SWOT and Corporate Finance Report Summary Ipsen S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Primary Health Care Ltd (PRY):企業の財務・戦略的SWOT分析
    Primary Health Care Ltd (PRY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Piller Group GmbH:企業の戦略的SWOT分析
    Piller Group GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • ARxIUM:医療機器:M&Aディール及び事業提携情報
    Summary ARxIUM, formerly Intelligent Hospital Systems Inc, a subsidiary of Van Humbeck Family, is a medical device company that designs and manufactures automated solutions for the hospital pharmacy. The company’s products include RxWorks pro, workflow, inventory management, IV compounding system, h …
  • Chubu Electric Power Co Inc (9502):企業の財務・戦略的SWOT分析
    Chubu Electric Power Co Inc (9502) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Autotelic Inc-製薬・医療分野:企業M&A・提携分析
    Summary Autotelic Inc (Autotelic) is a therapeutic drug monitoring company that develops novel treatments using its therapeutic drug monitoring (TDM) services. The company's pipeline products includes devices to improve safety and efficacy of COX-2 inhibitors, paclitaxel nanomedicine and TGF-beta in …
  • Lincoln Electric Holdings, Inc.:戦略・SWOT・企業財務分析
    Lincoln Electric Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Lincoln Electric Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Intertape Polymer Group Inc (ITP):企業の財務・戦略的SWOT分析
    Intertape Polymer Group Inc (ITP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • UNIQA Serbia:企業の戦略・SWOT・財務情報
    UNIQA Serbia - Strategy, SWOT and Corporate Finance Report Summary UNIQA Serbia - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • DSW Inc.:企業の戦略・SWOT・財務情報
    DSW Inc. - Strategy, SWOT and Corporate Finance Report Summary DSW Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • American Eagle Outfitters Inc:戦略・SWOT・企業財務分析
    American Eagle Outfitters Inc - Strategy, SWOT and Corporate Finance Report Summary American Eagle Outfitters Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Oklahoma Medical Research Foundation:製薬・医療:M&Aディール及び事業提携情報
    Summary Oklahoma Medical Research Foundation (OMRF) is a non-profit biomedical research institute. The institute conducts disease research for human diseases such as lupus, alzheimer’s and diseases of aging, diabetics, cancer, children’s disease, autoimmune disease and heart diseases. Its portfolio …
  • Owen Mumford Ltd:企業の戦略的SWOT分析
    Owen Mumford Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Daisy IT Group Ltd:企業の戦略的SWOT分析
    Daisy IT Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Wells Fargo & Co (WFC):電力:M&Aディール及び事業提携情報
    Summary Wells Fargo & Company (WFC) is a financial services holding company that provides retail, commercial and wholesale banking, and corporate banking services to individuals, businesses, high-net worth individuals, and institutions, through its subsidiaries. Its major offerings include commercia …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆